SLEEP AID COMPOSITION AND METHOD - A sleep composition including zolpidem and quetiapine in combination provides a healthy sleep pattern allowing the user to get seven or eight hours sleep. The amount of each ingredient in the combination is lower than the amount usually needed to provide this amount of sleep when the ingredients are being used alone.

Novel Ethanediamone Hepcidine Antagonists - The present invention relates to novel hepcidin antagonists of formula (I), pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for treatment of disorders in iron metabolism, such as, in particular, iron deficiency diseases and anaemias, in particular anaemias in connection with chronic inflammatory diseases (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

2012-08-23

20120214799

KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.

COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF - The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.

Novel Sulfonaminoquinoline Hepcidin Antagonists - The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

2012-08-23

20120214804

PHARMACEUTICAL COMPOSITION COMPRISING INDOLE COMPOUND - The present invention relates to a pharmaceutical composition comprising a compound of formula (1), (2) or (3) as defined in the specification for the prevention or treatment of diseases associated with oxidative stress, mitochondria dysfunction, hypoxic injury, necrosis and/or ischemic reperfusion injury, and a cosmetic composition comprising an indole compound having an antioxidant effect.

2012-08-23

20120214805

BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to Bridged Bicyclic Piperidine Derivatives, compositions comprising a Bridged Bi-cyclic Piperidine Derivative, and methods of using the Bridged Bicyclic Piperidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.

Aryl Urea Derivatives for Treating Obesity - A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.

2012-08-23

20120214809

Aminoindane Compounds and Use Thereof in Treating Pain - The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV 1 receptor activator. In one embodiment, the TRPV 1 receptor activator is lidocaine.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

2012-08-23

20120214812

COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).

2012-08-23

20120214813

ISOXAZOLE COMPOUND FOR THE TREATMENT OF CANCER - The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis.

METHODS AND COMPOSITIONS FOR SAFE AND EFFECTIVE TREATMENT OF ERYTHEMA - Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.4% to about 0.6% by weight of brimonidine and a pharmaceutically acceptable carrier.

2012-08-23

20120214817

UROTENSIN II RECEPTOR ANTAGONISTS - The invention is directed to Urotensin II antagonists. More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating Urotensin-II mediated disorders. Pharmaceutical and veterinary compositions and methods of treating cardiovascular disorders and various other disease states or conditions using compounds of the invention are also described.

2012-08-23

20120214818

METHODS OF TREATING DIASTOLIC DYSFUNCTION AND RELATED CONDITIONS - The invention provides a method of treating diastolic dysfunction, e.g., diastolic dysfunction with preserved ejection fraction, in a subject. The method comprises administering to the subject in an amount effective to treat the diastolic dysfunction a cardiac metabolic modifier, as described herein. In some embodiments, the diastolic dysfunction is characterized by (i) a lack of increased late I

Lipidomic Biomarkers of Diabetes - The invention, in some aspects, relates to methods for predicting a subject's risk of developing a glucose-related metabolic disorder, e.g., diabetes. In some aspects, the invention relates to methods for selecting and monitoring a treatment for a glucose-related metabolic disorder, e.g., diabetes.

NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula 1.0: (Formula (A1)), and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine ring that can have a bridge or a fused ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula A1.

2012-08-23

20120214824

PROTEOSTASIS REGULATORS - The present invention is directed to compounds of Formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.

2012-08-23

20120214825

mTOR/JAK INHIBITOR COMBINATION THERAPY - Provided herein is a combination therapy comprising an mTOR inhibitor and a JAK inhibitor. The combination therapy is useful for the treatment of a variety of cancers, including MPNs. The combination therapy is also useful for the treatment of any number of JAK-associated diseases.

2012-08-23

20120214826

INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Molecular Predictors of Therapeutic Response to Specific Anti-Cancer Agents - Herein is described the use of a collection of 50 breast cancer cell lines to match responses to 77 conventional and experimental therapeutic agents with transcriptional, proteomic and genomic subtypes found in primary tumors. Almost all compounds produced strong differential responses across the cell lines produced responses that were associated with transcriptional and proteomic subtypes and produced responses that were associated with recurrent genome copy number abnormalities. These associations can now be incorporated into clinical trials that test subtype markers and clinical responses simultaneously.

2012-08-23

20120214830

BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE INHIBITORS IN HEPATOCELLULAR CARCINOMA - The present invention provides diagnostic methods for predicting the effectiveness of treatment of an hepatocellular carcinoma (HCC) patient with an IGF-1R kinase inhibitor by assessing whether the HCC tumor cells express a high level of AFP, or whether serum levels of AFP protein are high. The present invention also provides diagnostic methods for predicting the effectiveness of treatment of cancer patients with IGF-1R kinase inhibitors, based on a determination of the expression level of IR, IGF-2, IGFBP3 or IGFBP7 in tumor cells, or a 4-gene index calculated using the expression vales for each of these four genes, which can be used to identify tumors that will be sensitive to IGF-1R kinase inhibitors, and also those that will be insensitive. Improved methods for treating cancer patients with IGF-1R kinase inhibitors that incorporate the above methods are also provided.

ISOFORM SELECTIVE PHOSPHOLIPASE D INHIBITORS - Disclosed are isoform selective Phospholipase D inhibitors. In one aspect, the disclosed compounds can have a structure represented by a formula (I): Also disclosed are methods of making and using the compounds. Also disclosed are pharmaceutical compositions and kits comprising the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IMMUNE ENHANCEMENT COMPOSITION AND KIT AND USE THEREOF - An immune enhancement composition is disclosed. The immune enhancement composition includes rapamycin, substituted quinoline and a pharmaceutically acceptable carrier, diluent, excipient or a combination thereof. An immune enhancement kit containing the two aforementioned compounds and a use of a combination containing the two aforementioned compounds as an immune enhancement composition are also disclosed. The application of the composition, kit and use is advantageous for promoting the activity of the immune system.

2012-08-23

20120214835

SENSITIZER, KIT AND USE FOR CANCER THERAPY - A cancer therapy sensitizer is disclosed. The cancer therapy sensitizer includes rapamycin and substituted quinoline. The present invention discloses a cancer therapy sensitization kit containing the two aforementioned compounds and a use of a combination of the two aforementioned compounds as a cancer therapy sensitizer as well. The application of the cancer therapy sensitizer, the kit and the use of the present invention is advantageous for improving the treatment effect of cancer therapies.

2012-08-23

20120214836

SENSITIZER, PHARMACEUTICAL COMPOSITION, KIT AND USE FOR TARGET THERAPY - A target therapy sensitizer including rapamycin and substituted quinoline is disclosed. In addition, a pharmaceutical composition containing the sensitizer, a target therapy sensitization kit containing the two aforementioned compounds, and a use of a combination of the two aforementioned compounds as a target therapy sensitizer are also disclosed. The application of the target therapy sensitizer, pharmaceutical composition, kit and use is advantageous for improving the treatment effect of target therapies.

INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE - Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.

METHODS FOR TREATING DISEASES OF THE RETINA - Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I

2012-08-23

20120214843

Combination Treatment of Hydroxpyridonate Actinide/Lanthanide Decorporation Agents - The invention provides for a method for treating a subject in need of such treatment comprising administering a therapeutically effective amount of one or more pharmaceutical compositions comprising a 1,2-HOPO chelating agent and a 3,2-HOPO chelating agent to a subject in need of such treatment. The use of both 1,2-HOPO and a 3,2-HOPO chelating agents in combination is more effective than using only one chelating agent alone. The invention is especially useful when practiced on a subject that has been exposed to, have been in contact with, or contaminated by one or more known or unknown actinides and/or lanthanides, or a mixture thereof.

2012-08-23

20120214844

Liquid Pest Control Formulation - The present invention relates to a liquid pest control system that includes a synthetic pyrethroid as a pest control active ingredient and an agent selected from the group consisting of purified diethylene glycol monoethyl ether, tocopherol nicotinate and tocopherol succinate, and combinations thereof, to reduce or eliminate paresthesia of the synthetic pyrethroid. The system releases the synthetic pyrethroid efficiently and uniformly. The pest control system is less irritating to the animal's skin as compared to prior art systems, particularly to small breeds of dogs. The system is useful for making liquid spot-on treatments, sprays and the like.

2012-08-23

20120214845

ACTIVE METABOLITE OF A THROMBIN RECEPTOR ANTAGONIST - Disclosed herein is an active metabolite (“M20”) of a molecule that is useful as a thrombin receptor antagonist: Also disclosed are formulations of this compound, synthetic routes to this compound, and methods of treating a variety of cardiovascular conditions, including acute coronary syndrome and peripheral arterial disease, and of effecting secondary prevention, by orally administering the active metabolilte.

COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES - The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.

2012-08-23

20120214851

Aminobenzamide Derivatives as Useful Agents for Controlling Animal Parasites - The invention relates to a composition comprising at least one aminobenzamide compound or a salt thereof for controlling animal parasites, veterinary pharmaceutical compositions comprising at least one aminobenzamide of formula (I) for preventing infection with diseases transmitted through parasites, its use for the preparation of a veterinary pharmaceutical for controlling animal parasites, and a method for preventing infection with diseases transmitted through parasites.

ITE for Cancer Intervention and Eradication - A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.

TREATMENT FOR CANCER - The present invention provides methods for the treatment of tumors, comprising administration of an effective amount of at least one taxoid and an effective amount of at least one benzimidazol carbamate compound of formula (I). The invention also provides a method for the treatment of tumors insensitive to one or more anti-mitotic drugs, the method comprising administering a effective amount of at least one benzimidazole carbamate compound of formula (I). Also provide are compositions for carrying out methods of the invention.

MODULATION OF FACTOR 7 EXPRESSION - Disclosed herein are antisense compounds and methods for decreasing Factor 7 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 7 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 7 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.

2012-08-23

20120214863

Anti-miR-1 Therapy for Wound Healing - Methods for modulating gene expression in a skin cell by administering to the cell an amount of a therapeutic composition in an amount sufficient to modulate the expression of miR-

2012-08-23

20120214864

MIRNAS DYSREGULATED IN TRIPLE-NEGATIVE BREAST CANCER - The invention provides methods of diagnosing and treating cancer in a subject. The inventors have identified a series of dysregulated miRNAs that are indicative of triple-negative breast cancer. In some embodiments, the invention further provides for the administration of a cancer therapy to the subject.

2012-08-23

20120214865

METHODS FOR SLOWING FAMILIAL ALS DISEASE PROGRESSION - Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.

2012-08-23

20120214866

TREATMENT WITH CYTOKINES - An inflammatory process is suggested to be involved in the pathogenesis of Alzheimer's disease (AD), a neurodegenerative disorder characterized by the presence of neuritic plaques within the cerebral cortex that are mainly composed of a small insoluble protein of 40-42 aminoacids (amyloid protein). Amyloid-specific Interleukin-10 (IL-10) generation is found to be selectively and significantly reduced in AD patients (p=0.023). The genotype associated with high IL-10 production is extremely infrequent in AD individuals (2% vs. 28%). The presence of low/intermediate-IL-10-producing genotypes (GCC/ATA; ATA/ATA) was associated with an earlier age at disease onset and (ACC/ACC; ACC/ATA) with an accelerated rate of disease progression/severity and with amyloid-specific impairment of IL-10 production. This relationship is independent of ApoE gene polymorphism. These results support the use of anti-inflammatory compounds in the therapy of this disease.

2012-08-23

20120214867

Bacteriophage T4 Nanoparticles for Eukaryotic Delivery - A T4 nanoparticle is a non-infectious, tail-less variant of a T4 bacteriophage. In one embodiment, eukaryotic cells are labeled with dyed T4 nanoparticles, wherein each dyed T4 nanoparticle comprises at least 350 dye molecules covalently bound thereto. In another embodiment, T4 nanoparticles are used to deliver exogenous DNA to eukaryotic cells for protein expression therein. It is contemplated that T4 nanoparticles may be used to deliver other exogenous material to eukaryotic cells.

2012-08-23

20120214868

Modified L-Nucleic Acid - A modified L-nucleic acid, containing an L-nucleic acid part conjugated to a non-L-nucleic acid part is described. The conjugate has extended retention time in and demonstrates a delayed elimination from an organism.

METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC FATIGUE SYNDROME - Methods for the diagnosis and treatment of chronic fatigue syndrome (CFS) are disclosed based upon the finding that particular individual acylcarnitines are present in modified concentrations (ie decreased or increased concentrations) in CFS patients compared to healthy control subjects. In one form of the invention, a diagnostic method comprises determining a concentration of at least one individual acylcarnitine compound (eg oleyl-L-carnitine and linoleyl-L-carnitine) in a body sample from a test subject and comparing the concentration to a reference concentration, wherein a difference in the concentration of the at least one individual acylcarnitine from the test subject compared to the reference concentration is indicative of CFS. In another form of the invention, a method of treating CFS is provided which comprises administering an effective amount of a supplement comprising: at least one acylcarnitine compound selected from short-chain, medium-chain and long-chain acylcarnitines, L-carnitine (or an acylcarnitine that may be converted within a subject to L-carnitine) in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids, or at least one acylcarnitine in combination with at least one fatty acid selected from short-chain, medium-chain and long-chain fatty acids.

BILE ACID OR BILE SALT FATTY ACID CONJUGATES - A method for treating a disease or disorder associated with altered glucose metabolism or insulin action in a subject in need thereof. The method includes administering to the subject a BAFAC (bile acid or bile salt fatty acid conjugate) of general formula II:

2012-08-23

20120214873

CYSTEINE FOR PHYSIOLOGICAL INJECTION - This application describes methods of making and using physiological cysteine solutions useful for reversing a neuromuscular blockade caused by a cysteine-reversible neuromuscular blockade agent, that overcomes problems of cysteine precipitation and dimerization.

2012-08-23

20120214874

PHARMACEUTICAL FORMULATIONS AND METHODS OF USE - In one embodiment, the present invention provides a topical composition including a topically acting anesthetic active ingredient; an ester; a non-ionic surfactant; a polar solvent; water, and optionally a buffer, a pH adjusting agent or an anti-oxidant. The compositions are useful for alleviating pain especially associated with acute herpes zoster.

2012-08-23

20120214875

PHENOXYBENZAMINE ASSAY - The invention provides methods for measuring concentrations of basic or neutral compounds, such as phenoxybenzamine, in biological samples, and methods for treating patients based on the compound concentrations in the biological samples from the patients.

2012-08-23

20120214876

Seizure and Migraine Treatments using the Bone Homeostasis Drug Cinacalcet - A novel pathogenesis underlying certain types of seizures and migraines is disclosed and the validated set of premises presented enable the deductive conclusion to be made that drugs that reduce the amount of calcium ions (Ca++) released from bone reduce seizure and migraine risk. The premises validated as true in the specifications include:

2012-08-23

20120214877

STABLE RASAGILINE COMPOSITION - The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders.

2012-08-23

20120214878

High Alcohol Content Sanitizer - This invention relates to an antimicrobial sanitizing composition in the form of a gel or cream that contains an alcohol in an amount of at least 55% by weight. The sanitizer is capable of disinfecting and providing prolonged antimicrobial property to a variety of surfaces, including the skin, without causing, drying, cracking, redness or irritation. In addition to alcohol, the sanitizer contains an anionic phospholipid in a controlled concentration as well as components conventionally found in skin creams and gels such as emulsifiers, emollients, moisturizers, rheology modifiers, and neutralizers. The anionic phospholipid enables use of the composition without the user experiencing dryness or irritation and the feeling of a greasy and unpleasant residue on the skin following use.

2012-08-23

20120214879

CHEMICAL SYSTEM WITH SELF-TIMING INDICATOR - A pH-modified luminescent composition and methods. In composition, a marker exhibiting luminescence change over a indicatory period. pH-based luminesce change may be in intensity or in wavelength. One embodiment provides a luminescent composition, including a selected luminescent marker having a first phase; and a selected ionizing agent comprising a second phase. The selected luminescent marker exhibits luminescence for an indicatory period responsive to intermixing of the first phase with the second phase. A selected antimicrobial agent combined with the first phase of the luminescent composition, wherein intermixing of the first phase with the second phase is at least a portion of a hand hygiene protocol. A method embodiment of using the luminescent composition, can include providing a luminescent marker; providing a ionizing agent; intermixing the luminescent marker with the ionizing agent; causing a change in pH in the selected luminescent marker; and exhibiting luminescence for a predetermined indicatory period.

2012-08-23

20120214880

CANCER SCREENING BY DETECTION OF ULTRASTRUCTURAL AND MOLECULAR MARKERS - The present invention relates to detection of cancer, or assessment of risk of development thereof. In particular, the present invention provides compositions and methods detection of field carcinogenesis by identification of ultrastructural and molecular markers in a subject.

2012-08-23

20120214881

TWO-STAGE GAS WASHING METHOD - The present description is related to the field of hydrocarbon production by gasification of carbonaceous material. It provides a two-stage gas washing method as a part of gas refining. More specifically it discloses a method for hydrogen sulfide and carbon dioxide removal from synthesis gas produced by gasification. It introduces a use of a novel combination of wash approaches for this application. As a specific application, this process is utilized as a part of biomass to liquid (BTL) process.

METHOD FOR PRODUCING SOLID ELECTROLYTE FILM - Disclosed is a method for producing a solid electrolyte film, which comprises: a formation step (A) in which a film that contains an electrolyte polymer is formed on a base; a separation step (B) in which the film formed on the base is separated from the base; a water washing step (C) in which the film obtained in the separation step (B) is water washed, while applying a tension (T

2012-08-23

20120214884

METHOD OF MAKING FLEXIBLE FOAMING MEMBER FROM RECYCLED MATERIALS - The present invention provides a method of making a flexible foaming member from recycled material. The present invention relates to a production method to recycling wastes containing rubber, plastic and metal materials and pulverize them into scraps under normal temperatures, then roughly separate the various materials contained in the waste scraps into different layers based on the difference of specific gravity, and further take out the scraps of rubber and plastic materials with lower specific gravity from the waste scraps, then conduct multiple heating and pulverizations under different temperatures to produce composite-material scraps, and then using some composite-material scraps to mix flexible materials and foaming agents, then pressing the mixture into a plate-like foaming material, and conduct vulcanization and foam forming for the plates of foam material to become a elastic foam.

2012-08-23

20120214885

FOAMABLE POLYSTYRENE RESIN PARTICLES AND PROCESS FOR PRODUCTION THEREOF, POLYSTYRENE RESIN PREFOAMED PARTICLES, POLYSTYRENE RESIN FOAM-MOLDED ARTICLE, HEAT-INSULATING MATERIAL FOR BUILDING MATERIAL, BANKING MEMBER, AND VEHICLE INTERIOR MATERIAL - In foamable polystyrene resin particles that are obtained by granulating a polystyrene resin containing a flame retardant and a foaming agent, the flame retardant has a bromine atom in a molecule, contains less than 70% by mass of bromine, has a benzene ring in a molecule, and has a 5% by mass decomposition temperature in a range of from 200° C. to 300° C., and a ratio (B/A) between (A) the amount of the flame retardant contained in the total foamable polystyrene resin particles and (B) the amount of the flame retardant contained in the surface of the resin particles is in a range of from 0.8 to 1.2. By pre-foaming the foamable polystyrene resin particles and then foaming the particles in a mold, a polystyrene resin foam-molded article having flame retardancy is obtained. According to the invention, it is possible to provide a the polystyrene resin foam-molded article that uses a flame retardant which is highly safe for the environment and living organisms, has a sufficient flame-retarding performance, and is excellent in mechanical strength, moldability, and exterior.

2012-08-23

20120214886

EXTRUDED PROPYLENE RESIN FOAM AND PROCESS FOR PRODUCTION THEREOF - Extruded propylene-based resin foam according to the present invention is formed by extrusion-foaming a propylene-based resin, and the extruded propylene-based resin foam has a closed cell content of less than 40% and an expansion ratio of 10 or more. Since the extruded propylene-based resin foam has an open-cell structure in which a cell-broken state is formed at a desired level and has a high expansion ratio, each cell in the foam has a sound absorption performance, such that the extruded foam is excellent in sound absorption performance.

2012-08-23

20120214887

Gypsum Wallboard Slurry and Method for Making the Same - A slurry for manufacturing gypsum board is disclosed. The slurry comprises calcined gypsum, water, a foaming agent, and a thickening agent. The thickening agent of the present disclosure acts to improve the cohesiveness of the slurry without adversely affecting the setting time of the slurry, the paper-to-core bond (wet and dry), or the head of the slurry by acting as a defoaming agent or coalescing agent. Examples of suitable thickening agents include cellulose ether and co-polymers containing varying degrees of polyacrylamide and acrylic acid. A gypsum board and method of forming the slurry and the gypsum board are also disclosed. The gypsum board comprises a gypsum layer formed from the slurry.

2012-08-23

20120214888

PROCESS FOR PREPARING A POLYURETHANE FOAM - The invention relates to a process for preparing a polyurethane foam, wherein a polyether polyol and a polyisocyanate are reacted in the presence of: a blowing agent; of from 1 to 30 ppmw, based on the polyether polyol, of metals derived from a composite metal cyanide complex catalyst; and of from 0.5 to 100 ppmw, based on the polyether polyol, of a phosphoric acid compound comprising a phosphoric acid selected from orthophosphoric acid, polyphosphoric acid and polymetaphosphoric acid, and/or a partial ester of such a phosphoric acid.